Ex-Bio­gen chief George Scan­gos to spear­head a Gates-backed start­up with big plans to fight in­fec­tious dis­eases

George Scan­gos

Ex-Bio­gen CEO George Scan­gos won’t be spend­ing much time be­tween jobs. Arch Ven­tures co-founder Robert Nelsen has re­cruit­ed Scan­gos to run an am­bi­tious new start­up of his fo­cused on amp­ing up an im­mune sys­tem at­tack on some per­ni­cious vi­ral and bac­te­r­i­al dis­eases like tu­ber­cu­lo­sis.

Nelsen, who nev­er does any­thing small, has al­ready com­mit­ted $150 mil­lion to the ven­ture — dubbed Vir Biotech­nol­o­gy. He’s be­ing joined by the Bill & Melin­da Gates Foun­da­tion along­side “sov­er­eign wealth funds, pub­lic mu­tu­al funds and promi­nent in­di­vid­u­als and fam­i­ly of­fices” that plan to put up hun­dreds of mil­lions more to back their work.

That mon­ey will be used to in-li­cense new pro­grams with an eye to quick­ly build­ing a pipeline of new ther­a­pies. For­mer Ver­tex Phar­ma­ceu­ti­cals pres­i­dent and Bio­gen Vice Pres­i­dent of Re­search and Sci­en­tif­ic Board mem­ber Vic­ki Sato will take on the chair­man’s role of the San Fran­cis­co-based com­pa­ny.

They’re get­ting start­ed with vi­ral vec­tors ob­tained in a buy­out of Tomega­Va, tech­nolo­gies orig­i­nal­ly de­vel­oped by a team at Ore­gon Health & Sci­ence Uni­ver­si­ty which was led by Louis Pick­er and Klaus Frueh.

“The scale and scope we en­vi­sion for Vir will al­low us to fund tar­get­ed aca­d­e­m­ic re­search, ramp our own re­search and de­vel­op­ment ef­forts, and write in­di­vid­ual checks of up to $100 mil­lion to in-li­cense in­no­v­a­tive tech­nol­o­gy plat­forms and nov­el clin­i­cal as­sets from biotech and phar­ma­ceu­ti­cal com­pa­nies,” said Nelsen.

That’s all in line with Nelsen’s Big Pic­ture think­ing at Arch, which has al­so backed Uni­ty, which is look­ing to be­come a pi­o­neer in an­ti-ag­ing R&D, and oth­er high fly­ing biotechs like Juno, one of the orig­i­nal CAR-T com­pa­nies now strug­gling with a dan­ger­ous lead pro­gram.

Scan­gos had this to say:

“The op­por­tu­ni­ty to lead Vir is one I could not pass up. There is a tremen­dous glob­al need for ef­fec­tive ther­a­pies and pre­ven­tions for in­fec­tious dis­eases of con­sid­er­able pub­lic health im­por­tance. Suc­cess would mean al­le­vi­a­tion of a lot of hu­man suf­fer­ing as well as mean­ing­ful fi­nan­cial re­turns for Vir in­vestors. The sci­ence has ma­tured to a point where ex­cit­ing new ap­proach­es are at hand, and there is a need for a com­pa­ny to pur­sue those ap­proach­es with ex­cel­lence, crit­i­cal mass and scale. Vir is that com­pa­ny, and I am very ex­cit­ed to take on a lead­er­ship role.”

Norbert Bischofberger. Kronos

Backed by some of the biggest names in biotech, Nor­bert Bischof­berg­er gets his megaround for plat­form tech out of MIT

A little over a year ago when I reported on Norbert Bischofberger’s jump from the CSO job at giant Gilead to a tiny upstart called Kronos, I noted that with his connections in biotech finance, that $18 million launch round he was starting off with could just as easily have been $100 million or more.

With his first anniversary now behind him, Bischofberger has that mega-round in the bank.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,100+ biopharma pros reading Endpoints daily — and it's free.

Francesco De Rubertis

Medicxi is rolling out its biggest fund ever to back Eu­rope's top 'sci­en­tists with strange ideas'

Francesco De Rubertis built Medicxi to be the kind of biotech venture player he would have liked to have known back when he was a full time scientist.

“When I was a scientist 20 years ago I would have loved Medicxi,’ the co-founder tells me. It’s the kind of place run by and for investigators, what the Medicxi partner calls “scientists with strange ideas — a platform for the drug hunter and scientific entrepreneur. That’s what I wanted when I was a scientist.”

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,100+ biopharma pros reading Endpoints daily — and it's free.

Af­ter a decade, Vi­iV CSO John Pot­tage says it's time to step down — and he's hand­ing the job to long­time col­league Kim Smith

ViiV Healthcare has always been something unique in the global drug industry.

Owned by GlaxoSmithKline and Pfizer — with GSK in the lead as majority owner — it was created 10 years ago in a time of deep turmoil for the field as something independent of the pharma giants, but with access to lots of infrastructural support on demand. While R&D at the mother ship inside GSK was souring, a razor-focused ViiV provided a rare bright spot, challenging Gilead on a lucrative front in delivering new combinations that require fewer therapies with a more easily tolerated regimen.

They kept a massive number of people alive who would otherwise have been facing a death sentence. And they made money.

And throughout, John Pottage has been the chief scientific and chief medical officer.

Until now.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,100+ biopharma pros reading Endpoints daily — and it's free.

Chas­ing Roche's ag­ing block­buster fran­chise, Am­gen/Al­ler­gan roll out Avastin, Her­ceptin knock­offs at dis­count

Let the long battle for biosimilars in the cancer space begin.

Amgen has launched its Avastin and Herceptin copycats — licensed from the predecessors of Allergan — almost two years after the FDA had stamped its approval on Mvasi (bevacizumab-awwb) and three months after the Kanjinti OK (trastuzumab-anns). While the biotech had been fielding biosimilars in Europe, this marks their first foray in the US — and the first oncology biosimilars in the country.

Seer adds ex-FDA chief Mark Mc­Clel­lan to the board; Her­cules Cap­i­tal makes it of­fi­cial for new CEO Scott Bluestein

→ On the same day it announced a $17.5 million Series C, life sciences and health data company Seer unveiled that it had lured former FDA commissioner and ex-CMS administrator Mark McClellan on to its board. “Mark’s deep understanding of the health care ecosystem and visionary insights on policy reform will be crucial in informing our thinking as we work to bring our liquid biopsy and life sciences products to market,” said Seer chief and founder Omid Farokhzad in a statement.

Daniel O'Day

No­var­tis hands off 3 pre­clin­i­cal pro­grams to the an­tivi­ral R&D mas­ters at Gilead

Gilead CEO Daniel O’Day’s new task hunting up a CSO for the company isn’t stopping the industry’s dominant antiviral player from doing pipeline deals.

The big biotech today snapped up 3 preclinical antiviral programs from pharma giant Novartis, with drugs promising to treat human rhinovirus, influenza and herpes viruses. We don’t know what the upfront is, but the back end has $291 million in milestones baked in.

Vas Narasimhan, AP Images

On a hot streak, No­var­tis ex­ecs run the odds on their two most im­por­tant PhI­II read­outs. Which is 0.01% more like­ly to suc­ceed?

Novartis CEO Vas Narasimhan is living in the sweet spot right now.

The numbers are running a bit better than expected, the pipeline — which he assembled as development chief — is performing and the stock popped more than 4% on Thursday as the executive team ran through their assessment of Q2 performance.

Year-to-date the stock is up 28%, so the investors will be beaming. Anyone looking for chinks in their armor — and there are plenty giving it a shot — right now focus on payer acceptance of their $2.1 million gene therapy Zolgensma, where it’s early days. And CAR-T continues to underperform, but Novartis doesn’t appear to be suffering from it.

So what could go wrong?

Actually, not much. But Tim Anderson at Wolfe pressed Narasimhan and his development chief John Tsai to pick which of two looming Phase III readouts with blockbuster implication had the better odds of success.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,100+ biopharma pros reading Endpoints daily — and it's free.

On a glob­al romp, Boehringer BD team picks up its third R&D al­liance for Ju­ly — this time fo­cused on IPF with $50M up­front

Boehringer Ingelheim’s BD team is on a global deal spree. The German pharma company just wrapped its third deal in 3 weeks, going back to Korea for its latest pipeline pact — this time focused on idiopathic pulmonary fibrosis.

They’re handing over $50 million to get their hands on BBT-877, an ATX inhibitor from Korea’s Bridge Biotherapeutics that was on display at a science conference in Dallas recently. There’s not a whole lot of data to evaluate the prospects here.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,100+ biopharma pros reading Endpoints daily — and it's free.

Servi­er scoots out of an­oth­er col­lab­o­ra­tion with Macro­Gen­ics, writ­ing off their $40M

Servier is walking out on a partnership with MacroGenics $MGNX — for the second time.

After the market closed on Wednesday MacroGenics put out word that Servier is severing a deal — inked close to 7 years ago — to collaborate on the development of flotetuzumab and other Dual-Affinity Re-Targeting (DART) drugs in its pipeline.

MacroGenics CEO Scott Koenig shrugged off the departure of Servier, which paid $20 million to kick off the alliance and $20 million to option flotetuzumab — putting a heavily back-ended $1 billion-plus in additional biobuck money on the table for the anti-CD123/CD3 bispecific and its companion therapies.